Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… led to lower number of immediate and delayed postoperative bleeding episodes… compared with placebo (placebo solution/mouthwash); GRADE not reported.
1 finding from 1 review
Any postoperative complication except bleeding (e.g. wound infection) · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in any postoperative complication except bleeding (e.g. wound infection) compared with placebo (placebo solution/mouthwash); GRADE not reported.
1 finding from 1 review
Number of participants with postoperative bleedings requiring intervention · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… probably leads to lower number of participants with postoperative bleedings requiring… compared with placebo (placebo solution/mouthwash) (moderate certainty).
1 finding from 1 review
Amount of postoperative blood loss (mL) · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
0 studies
No studies found
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 5, Safety of the intervention up to 3 months: 'All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was…
1 study
GRADE not reported
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
Systemic beta carotene or carotenoids (incl. lycopene) may leads to lower improvement of histological features (not improved) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 6, Histological changes: 'Not measured'. Effects text: data on histological changes from Armstrong 2013 were not available for analysis, but study authors reported no statistically significant differences in…
1 study
GRADE not reported
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
Vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic… probably leads to lower improvement of histological features (not improved) compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 2, Safety of the intervention at 5 to 12 months: 'Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d (Nagao), and caused adverse effects of varying severity in 9% of…
3 studies
GRADE not reported
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Surgical removal of the lesion (surgical excision, laser surgery, cryotherapy) vs Placebo or no treatment
Outcome not reported · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
'We did not identify any RCTs that compared surgical treatments with placebo or no treatment.' Three surgical RCTs were found (Chee 2013, Lopez-Jornet 2013, Schwarz 2005) but all excluded because they did not include a…
Studies not reported
No studies found
Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes improvement of histological features (not improved) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Removal of predisposing habits (e.g. tobacco/alcohol cessation) vs Placebo or no treatment
Outcome not reported · People with a diagnosis of oral leukoplakia
The review found no eligible studies for this question.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
4 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Non-specific immunotherapy (recombinant interleukin-2 or BCG cell… showed no clear difference in adverse effects compared with standard therapy alone; GRADE not reported.
9 findings from 1 review
RR 11.00 [0.67, 179.29]
1 study · 24 participants
GRADE not reported
RR 3.40 [0.15, 77.34]
1 study · 30 participants
GRADE not reported
RR 1.47 [0.75, 2.90]
1 study · 30 participants
GRADE not reported
Show 6 more findings
RR 0.57 [0.22, 1.50]
1 study · 30 participants
GRADE not reported
RR 0.67 [0.13, 3.30]
1 study · 24 participants
GRADE not reported
RR 0.38 [0.04, 3.26]
1 study · 30 participants
GRADE not reported
RR 1.24 [0.90, 1.70]
1 study · 30 participants
GRADE not reported
RR 1.71 [0.33, 8.83]
1 study · 30 participants
GRADE not reported
RR 5.00 [0.27, 94.34]
1 study · 24 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
Tyrosine kinase inhibitor (erlotinib, gefitinib or lapatinib) plus… led to higher adverse effects compared with standard therapy alone (radiotherapy or chemoradiotherapy); GRADE not reported.
9 findings from 1 review
RR 2.02 [1.23, 3.32]
1 study · 67 participants
GRADE not reported
RR 1.04 [0.98, 1.11]
1 study · 226 participants
GRADE not reported
RR 15.53 [2.18, 110.55]
1 study · 67 participants
GRADE not reported
Show 6 more findings
RR 6.57 [3.60, 12.00]
1 study · 191 participants
GRADE not reported
RR 1.22 [0.96, 1.56]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.94, 1.11]
2 studies · 286 participants
GRADE not reported
RR 1.03 [0.82, 1.28]
2 studies · 286 participants
GRADE not reported
RR 1.11 [0.83, 1.49]
3 studies · 484 participants
GRADE not reported
RR 1.25 [0.54, 2.88]
4 studies · 544 participants
GRADE not reported
Adverse effects · People with squamous cell carcinoma of the oral cavity or oropharynx
10 findings from 1 review
Mucositis all grades: not estimable due to high heterogeneity (P=0.0009; I2=86%) between subgroups (cetuximab; nimotuzumab) and within cetuximab (I2=93%); 1417 participants, 3 studies. Table 3, row 1.6 (Ang 2014;…
3 studies · 1417 participants
GRADE not reported
RR 6.56 [5.35, 8.03]
2 studies · 1311 participants
GRADE not reported
RR 1.36 [0.80, 2.31]
2 studies · 1311 participants
GRADE not reported
Show 7 more findings
Disease-free survival · People with squamous cell carcinoma of the oral cavity or oropharynx
It is very uncertain whether non-specific immunotherapy (recombinant interleukin-2 or BCG cell… changes disease-free survival compared with standard therapy alone (very low certainty).
1 finding from 1 review